surmount-1 trial tirzepatide weight loss nondiabetic obesity without diabetes non-diabetic once weekly for the treatment of in people with type 2 ( SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 SURMOUNT-1: Tirzepatide Drastically Tirzepatide vs semaglutide: A new

"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." New England Journal of Medicine, 2021, 385(6), 503-515

No third-party reviews yetVerified Aug 1, 2026SourceVisit site$198/mo all-in monthly they advertise $99 SesameCert

Still, healthcare professionals may recommend taking these drugs together, at least for a short period, to help kickstart weight loss

With our expert care, comprehensive membership benefits, and flexible Klarna payment options, theres never been a better time to invest in your health

The recommended washout period differs by product: the UK Summary of Product Characteristics (SmPC) for semaglutide (Wegovy) advises stopping treatment at least two months before a planned pregnancy, whilst the SmPC for tirzepatide (Mounjaro) advises stopping at least one month before